View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
For questions about content or obtaining CME credit, please contact the Endocrine Society at www.education.endocrine.org/contact.
Concise CCO expert commentary on potential side effects with GLP-1 receptor agonists in patients with type 2 diabetes
Martin J. Abrahamson, MD, FACP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: September 1, 2020
Expired:
August 31, 2021
Neil Skolnik, MD reviews GLP-1 RAs to address elevated A1C, obesity, and CV risk, plus strategies to improve tolerability, adherence
John J. Russell, MD
Neil Skolnik, MD
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Nurse Practitioners:
1.0 AANP contact hour
Released: July 13, 2020
Expired:
July 12, 2021
Hyperglycemia can be a deadly complication for anyone with diabetes, but there are tools that can reduce this risk including GLP-1 medications. Learn more today.
CME commentary: GLP-1 receptor agonists to prevent major cardiovascular adverse events (MACE) in type 2 diabetes (T2D), cardiovascular disease (CVD)
Anne Peters, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.25 Nursing contact hours
Released: June 8, 2020
Expired:
June 7, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.